Investig Clin Urol.  2019 Jul;60(4):244-250. 10.4111/icu.2019.60.4.244.

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide

Affiliations
  • 1Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. js315@hallym.or.kr

Abstract

PURPOSE
To investigate the changes in testosterone levels and rates of chemical castration following androgen-deprivation therapy (ADT) with goserelin, triptorelin, and leuprolide.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015. Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model. The number of patients with serum testosterone below castration levels defined as various values (<50 ng/dL, <20 ng/dL, or <10 ng/dL) at 3, 6, and 9 months were also evaluated.
RESULTS
Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively. The lowest mean testosterone levels during 9 months of treatment were achieved in patients treated with triptorelin, followed by those treated with leuprolide, and then by those treated with goserelin (p=0.001). Significant differences in chemical castration levels were observed only at <10 ng/dL, with 54.2% of goserelin, 93.2% of triptorelin, and 86.4% of leuprolide treated patients (p<0.001).
CONCLUSIONS
Three LHRH agonists showed comparable efficacy for achieving castration when the castration threshold was 50 or 20 ng/dL. However, triptorelin was the most potent LHRH agonist, achieving the lowest mean testosterone levels and the highest rate of chemical castration at <10 ng/dL testosterone.

Keyword

Antineoplastic agents; Prostatic neoplasms; Prostate-specific antigen; Testosterone

MeSH Terms

Antineoplastic Agents
Castration*
Gonadotropin-Releasing Hormone*
Goserelin*
Humans
Leuprolide*
Lutein*
Medical Records
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Retrospective Studies
Testosterone
Triptorelin Pamoate*
Antineoplastic Agents
Gonadotropin-Releasing Hormone
Goserelin
Leuprolide
Lutein
Prostate-Specific Antigen
Testosterone
Triptorelin Pamoate
Full Text Links
  • ICU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error